Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | BRAF |
Variant | F247L |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | BRAF F247L lies within the phorbol-ester/DAG-type zinc finger domain of the Braf protein (UniProt.org). F247L confers a gain of function to Braf, as indicated by activation of downstream MAPK signaling and is transforming in cultured cells (PMID: 28512244, PMID: 29533785). |
Associated Drug Resistance | |
Category Variants Paths |
BRAF mutant BRAF act mut BRAF F247L |
Transcript | NM_004333.6 |
gDNA | chr7:g.140801533A>G |
cDNA | c.739T>C |
Protein | p.F247L |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_047420768.1 | chr7:g.140801533A>G | c.739T>C | p.F247L | RefSeq | GRCh38/hg38 |
NM_001378469.1 | chr7:g.140801533A>G | c.739T>C | p.F247L | RefSeq | GRCh38/hg38 |
XM_017012558.1 | chr7:g.140801533A>G | c.739T>C | p.F247L | RefSeq | GRCh38/hg38 |
NM_001354609.1 | chr7:g.140801533A>G | c.739T>C | p.F247L | RefSeq | GRCh38/hg38 |
XM_047420769.1 | chr7:g.140801533A>G | c.739T>C | p.F247L | RefSeq | GRCh38/hg38 |
XM_017012559.1 | chr7:g.140801533A>G | c.739T>C | p.F247L | RefSeq | GRCh38/hg38 |
NM_001374244.1 | chr7:g.140801533A>G | c.739T>C | p.F247L | RefSeq | GRCh38/hg38 |
XM_017012558 | chr7:g.140801533A>G | c.739T>C | p.F247L | RefSeq | GRCh38/hg38 |
NM_001374258.1 | chr7:g.140801533A>G | c.739T>C | p.F247L | RefSeq | GRCh38/hg38 |
NM_001378468.1 | chr7:g.140801533A>G | c.739T>C | p.F247L | RefSeq | GRCh38/hg38 |
NM_004333 | chr7:g.140801533A>G | c.739T>C | p.F247L | RefSeq | GRCh38/hg38 |
NM_004333.5 | chr7:g.140801533A>G | c.739T>C | p.F247L | RefSeq | GRCh38/hg38 |
NM_001378471.1 | chr7:g.140801533A>G | c.739T>C | p.F247L | RefSeq | GRCh38/hg38 |
XM_005250045 | chr7:g.140801533A>G | c.739T>C | p.F247L | RefSeq | GRCh38/hg38 |
NM_001354609.2 | chr7:g.140801533A>G | c.739T>C | p.F247L | RefSeq | GRCh38/hg38 |
NM_004333.6 | chr7:g.140801533A>G | c.739T>C | p.F247L | RefSeq | GRCh38/hg38 |
XM_047420767.1 | chr7:g.140801533A>G | c.739T>C | p.F247L | RefSeq | GRCh38/hg38 |
XM_017012559 | chr7:g.140801533A>G | c.739T>C | p.F247L | RefSeq | GRCh38/hg38 |
NM_001378474.1 | chr7:g.140801533A>G | c.739T>C | p.F247L | RefSeq | GRCh38/hg38 |
XM_017012559.2 | chr7:g.140801533A>G | c.739T>C | p.F247L | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF F247L | Advanced Solid Tumor | sensitive | Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing BRAF F247L demonstrated sensitivity to Mekinist (trametinib) in culture (PMID: 28512244). | 28512244 |
BRAF F247L | Advanced Solid Tumor | sensitive | Dabrafenib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing BRAF F247L demonstrated sensitivity to Tafinlar (dabrafenib) in culture (PMID: 28512244). | 28512244 |
BRAF F247L | colorectal cancer | not predictive | Cetuximab + Fluorouracil + Irinotecan + Leucovorin | Case Reports/Case Series | Actionable | In a clinical study, the combination of Erbitux (cetuximab) with FOLFIRI as a third-line therapy resulted in a complete response with regression of the thoracic nodes and progression-free survival lasting 12.6 months in a patient with metastatic colorectal cancer harboring BRAF F247L (PMID: 31515458). | 31515458 |